Rockland Trust Co. Has $18.99 Million Stake in Johnson & Johnson $JNJ

Rockland Trust Co. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 102,425 shares of the company’s stock after selling 4,972 shares during the quarter. Rockland Trust Co.’s holdings in Johnson & Johnson were worth $18,992,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson in the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Compass Financial Services Inc raised its stake in shares of Johnson & Johnson by 707.1% during the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after buying an additional 198 shares during the last quarter. Finally, Signature Resources Capital Management LLC increased its holdings in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.6%

JNJ opened at $238.62 on Tuesday. The firm has a market capitalization of $574.90 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 2.33 and a beta of 0.35. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a fifty day moving average price of $214.20 and a 200-day moving average price of $194.70. Johnson & Johnson has a one year low of $141.50 and a one year high of $240.93.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. During the same quarter in the previous year, the company posted $2.04 EPS. Johnson & Johnson’s quarterly revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s payout ratio is presently 47.06%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Morgan Stanley set a $262.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Guggenheim upped their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.